TRANSCENTA HOLDING - A global Fully Integrated Biotherapeutics Company

Transcenta, biologics, antibody

TRANSCENTA HOLDING - A global Fully Integrated Biotherapeutics Company

contact 中文

Pipeline

Transcenta has established a pipeline of over ten innovative molecules in oncology, bone disorders and nephrology. Most of these are discovered and developed in house and some are acquired through in-licensing.

Program

Target

Indication

Pre-clinical

IND Filing

Ph I

Ph II

Ph III

NDA/BLA Filing

Territory

MSB2311

PD-L1

Solid Tumors

MSB2311 - PD-L1 - Solid Tumors

Territory:Global

Global

TST001

Claudin 18.2

Solid Tumors

TST001 - Claudin 18.2 - Solid Tumors

Territory:Global

Global

MSB0254

VEGFR2

Solid Tumors

MSB0254 - VEGFR2 - Solid Tumors

Territory:Global

Global

JCT205

DR5

Solid Tumors

JCT205 - DR5 - Solid Tumors

Territory:Greater China(In-licensed from InhibRx)

Greater China(In-licensed from InhibRx)

TST005

PDL1-TGFβ Bispecific

Solid Tumors

TST005 - PDL1-TGFβ Bispecific - Solid Tumors

Territory:Global

Global

TST002

Sclerostin

Osteoporosis

TST002 - Sclerostin - Osteoporosis

Territory:Greater China (In-licensed from
Eli Lilly)

Greater China (In-licensed from
Eli Lilly)

TST004

MASP2

Nephrology

TST004 - MASP2 - Nephrology

Territory:Global

Global

TST003

Undisclosed

Solid Tumors

TST003 - Undisclosed - Solid Tumors

Territory:Global

Global

TST006

Undisclosed

Oncology

TST006 - Undisclosed - Oncology

Territory:Global

Global

TST007

Undisclosed

Oncology

TST007 - Undisclosed - Oncology

Territory:Global

Global

TST008

Undisclosed

Nephrology

TST008 - Undisclosed - Nephrology

Territory:Global

Global

Non-oncology

Oncology

  • Program:

    MSB2311
  • Target:

    PD-L1
  • Indication:

    Solid Tumors

brief introduction:

Albert has 15 years of experience in the financial field and has worked in the Audit and Trading Consulting department of PWC, providing IPO audits, annual audits, transaction due diligence, post management, transaction integration and other related financial advisory services. Over the past 10 years, he has been responsible for assisting clients to list in mainland China and Hong Kong's capital markets by verifying compliance with the rules of relevant capital market regulation and reporting.